Lung Cancer
Latest News
Monotherapy or one-two punch against EGFR-mutant NSCLC?
Clinicians debate whether combining other drugs with osimertinib adds anything but toxicity to the care of patients with EGFR-mutated NSCLC.
Latest News
Expert views diverge on adding chemotherapy to EGFR TKIs in EGFR-mutant NSCLC
Two physicians weigh the pros and cons of monotherapy over combination therapy for non–small cell lung cancer.
Latest News
Abraxane still in short supply for cancer patients
Allotments for this chemotherapy drug are waning but patients are willing to travel for treatment.
From the Journals
U.S. cancer deaths continue to fall, especially lung cancer
There has been an overall decline of 32% in cancer deaths as of 2019.
Latest News
Lung cancer risk misperceptions impede lifesaving screenings
More intensive, repeated, and wide-reaching outreach efforts may be necessary to encourage more high-risk men and women to undergo lung cancer...
Latest News
NSCLC therapies associated with cardiac events
Several targeted NSCLC therapies are strongly associated with cardiac adverse events, such as conduction disease, QT prolongation, and heart...
Latest News
EMA panel endorses two cancer drugs, one sickle cell drug
Tepotinib for NSCLC, enfortumab vedotin for urothelial cancer and voxelotor for sickle cell disease are currently approved in the U.S.
Latest News
Earlier lung cancer detection may drive lower mortality
Few eligible patients undergo CT screening despite survival benefits.
Feature
What causes cancer? There’s a lot we don’t know
Obesity status over time may be more relevant to cancer risk than one-off measures.
Opinion
Benefits of low-dose CT scanning for lung cancer screening explained
CHEST gives 18 recommendations and further evidence of the benefits of CT screening.